報價延遲最少15分鐘:2026/04/12 10:52 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.15/1.33
|
|
企業價值
981.88M
|
| 資產負債 |
|
每股賬面淨值
-1.61
|
| 現金流量 |
|
現金流量率
0.22
|
| 損益表 |
|
收益
296.15M
|
|
每股收益
2.62
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries. |
